Evidence map›Paper›PMID 33908000›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Fast Afucosylation Profiling of Glycoengineered Antibody Subunits by Middle-Up Mass Spectrometry.

Elsa Wagner-Rousset, Olivier Colas, Stéphane Chenu, Yannis-Nicolas François, Davy Guillarme, Sarah Cianferani, Yury O Tsybin, Jonathan Sjögren, Arnaud Delobel, Alain Beck

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. QuantitativePharmaceutics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Elsa Wagner-RoussetPierre Fabre Laboratories, IRPF-Centre d'Immunologie Pierre-Fabre (CIPF), Saint-Julien-en-Genevois, France.
Olivier ColasPierre Fabre Laboratories, IRPF-Centre d'Immunologie Pierre-Fabre (CIPF), Saint-Julien-en-Genevois, France.
Stéphane ChenuPierre Fabre Laboratories, IRPF-Centre d'Immunologie Pierre-Fabre (CIPF), Saint-Julien-en-Genevois, France.
Yannis-Nicolas FrançoisLaboratoire de Spectrométrie de Masse des Interactions et des Systèmes (LSMIS), UMR 7140, Université de Strasbourg, CNRS, Strasbourg, France.
Davy GuillarmeSchool of Pharmaceutical Sciences, University of Geneva, CMU, Geneva, Switzerland.
Sarah CianferaniLaboratoire de Spectrométrie de Masse BioOrganique, IPHC UMR 7178, Université de Strasbourg, CNRS, Strasbourg, France.
Yury O TsybinSpectroswiss Sarl, EPFL Innovation Park, Lausanne, Switzerland.
Jonathan SjögrenGenovis AB, Lund, Sweden.
Arnaud DelobelQuality Assistance SA, Donstiennes, Belgium.
Alain BeckPierre Fabre Laboratories, IRPF-Centre d'Immunologie Pierre-Fabre (CIPF), Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com.
Center of Immunology Pierre Fabre · FRUniversité de Strasbourg · FRÉcole Polytechnique Fédérale de Lausanne · CHGenovis (Sweden) · SEUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Middle-up LC-MS antibody characterization workflows using reduction or IdeS digestion for a focused assessment of N-glycan profiling of three representative glycoengineered monoclonal antibodies (mAbs), namely, obinutuzumab (GlycomAb technology, Glycart/Roche), benralizumab (Potelligent Technology, BioWa, Kyowa Kirin) and mAb B (kifunensine) and compared to mAb A, produced in a common CHO cell line. In addition, EndoS or EndoS2 enzyme are used for quantitative determination of Fc-glycan core afucosylation and high mannose for these antibodies, as requested by health authorities for Fc-competent therapeutics mAbs critical quality attributes (CQAs).

Indexed as

Protein EngineeringProtein Processing, Post-TranslationalSpectrometry, Mass, Electrospray IonizationAlkaloidsAnimalsAntibodies, Monoclonal, HumanizedCHO CellsChromatography, LiquidCricetulusGlycosylationResearch DesignWorkflowAlkaloidsAntibodies, Monoclonal, HumanizedbenralizumabkifunensineobinutuzumabADCCBenralizumabEndoSEndoS2High mannoseIdeSKifunensineLow fucoseMass spectrometryObinutuzumab

Identifiers

PMID33908000
OpenAlexW3159324822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.